back to US directory
us clinical guidance

Stable angina and chronic coronary disease

US symptom control, event prevention, exercise, testing and revascularization priorities for chronic coronary disease with angina.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with chronic coronary disease and stable anginal symptoms, including obstructive or nonobstructive CAD, prior myocardial infarction or revascularization and chronic ischemic syndromes. New, rest, accelerating or otherwise unstable symptoms move to the acute chest-pain or ACS pathway.
sources for this section:AHA/ACC CCD 2023

The Bottom Line

  • Use a patient-centered, team-based plan combining symptom relief, prevention of future cardiovascular events, physical activity, tobacco cessation and management of lipids, blood pressure and diabetes.
  • Use a beta blocker, calcium-channel blocker or long-acting nitrate as first-line antianginal therapy according to comorbidity and tolerance; add another class when symptoms persist.
  • Statins are first-line lipid therapy in chronic coronary disease, with evidence-based nonstatin intensification when risk and achieved LDL response warrant it.
  • Do not perform routine periodic anatomic or ischemic testing without a change in clinical or functional status when the result will not alter treatment.
  • For lifestyle-limiting angina despite guideline-directed medical therapy, discuss revascularization to improve symptoms using anatomy, procedural risk and patient preference.
sources for this section:AHA/ACC CCD 2023

Practical clinical workflow

1
Confirm symptom stability, functional limitation, prior anatomy and revascularization, ventricular function, adherence and alternative explanations for chest discomfort.
2
Review ECG and available imaging, then select further testing only when symptoms, risk or a management decision justifies it.
3
Optimize antianginal therapy and secondary prevention, including lipid lowering, blood pressure, diabetes, exercise, cardiac rehabilitation and tobacco treatment.
4
Reassess angina frequency, activity, adverse effects, adherence and goals; provide a clear action plan for symptom change.
5
Refer for coronary anatomy and revascularization discussion when symptoms remain limiting, high-risk disease is suspected or ventricular function deteriorates.
sources for this section:AHA/ACC CCD 2023

Safety boundaries and escalation

  • Rest pain, accelerating frequency, prolonged symptoms, diaphoresis, dyspnea, syncope or poor response to the established plan requires urgent ACS assessment.
  • Avoid phosphodiesterase-5 inhibitors with nitrate therapy and review bradycardia, hypotension, conduction disease and interactions when combining antianginals.
  • Do not continue beta blockers solely by habit after remote myocardial infarction when there is no current indication; reassess against the 2023 guideline and ventricular function.
  • New heart failure, arrhythmia or marked functional decline should prompt timely cardiac reassessment rather than automatic dose escalation.
sources for this section:AHA/ACC CCD 2023

Localization

Use the 2023 ACC/AHA chronic-coronary-disease guideline and current US FDA labels. Cardiac-rehabilitation and testing coverage varies by payer and site.
sources for this section:AHA/ACC CCD 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2023 Guideline for the Management of Patients With Chronic Coronary DiseaseDOI 10.1161/CIR.0000000000001168 路 published 2023-07-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.